Notably: BPC-157, KPV, MOTs-C, Emideltide (DSIP), Epitalon, Semax (heptapeptide) and TB-500 are among those expected to be reviewed in July 2026 Other substances, including Cathelicidin LL-37, Dihexa Acetate, PEG-MGF, GHK-Cu and Melanotan II, are under consideration for review by early 2027 Non-injectable GHK-Cu is following a slightly different path, with separate evaluation anticipated before February 2027
Many successful recoveries take eight to twelve weeks
Get 10% off your first order Want regular tips on how to make the most of your results
In this guide, well provide an in-depth look at peptide therapy versus testosterone replacement so you can make an informed decision on the best approach for your needs
Most of the tested samples (74.6%, n = 47) were in tablet form intended for oral administration (Figure 3), while 25.4% were presented as powders for injections (n = 16)